Innate immunity’s role in pancreatic cancer is complex. It impacts inflammation, immune surveillance, and the tumor microenvironment, influencing disease progression and potential treatments.
Innovation in pancreatic cancer: Acobiom develops the 1st blood-based diagnostic to identify the patients most likely to benefit from FOLFIRINOX as 1st-line treatment.
Pancreatic ductal adenocarcinoma (PDAC, representing more than 90% of pancreatic cancer cases is a highly lethal cancer, and chemotherapy is a key treatment for advanced PDAC. Gemcitabine chemotherapy is still an important component of treatment. Although, according to several clinical trials (Conroy, T. et al. N Engl J Med. 2011; Von Hoff, D. et al.…
Read more
• CE marked test for patients with pancreatic ductal adenocarcinoma
• Prediction of response to first-line gemcitabine-based chemotherapy
• Developed and validated with real world data and samples
Pancreatic cancer is a highly lethal cancer. For several years, gemcitabine has been one of the main chemotherapies used to treat this cancer. But there is no routine biomarker to predict its efficacy.
Dr. Noelle LoConte presented the results of using GemciTest® in a confirmatory study, which shows the predictive performance of this in-vitro diagnostic based on PCR technology and a blood RNA signature.
The French Association of Competitiveness Poles (FACP) awards ACOBIOM the hi-France label, the label of innovative companies to invest in.
Based on Real-World Data and Real-World Evidence, ACOBIOM contributes to better therapeutic decisions and thus allows to give the right treatment to the right patient.
Based on its proprietary database of gene expression profiles and its scientific expertise, ACOBIOM selected a panel of genes to measure inflammation in organs and blood. This Digital or Real-Time PCR assay allows the company to extend its range of services.
Gene expression analyses by real-time PCR (or qPCR) are currently used to measure drug effects or to identify subpopulations of patients mostly likely to benefit from a specific therapy. The success of a qPCR experiment relies on the combination of a unique triptych: the selection of relevant and regulated target genes, the identification of a couple or more stable and experiment-specific reference genes, also called housekeeping genes, and robust statistical analyses. Thus, if some consider the target genes as the Kings of their experiment, the reference genes are the Queens of the equation!
ACOBIOM is involved in a national collaborative clinical research program: OncoSNIPE®, whose objectives are to identify early and late markers of resistance to 1st line treatments in locally advanced or metastatic triple negative breast cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma. In this project, the scientific team of the company develops an optimized pipeline of bioinformatics and biostatistics tools to perform in routine, in blood and tissue, DNA and RNA analyses from hundreds of sequencing experiments.
These types of approaches associated with standardized protocols are applied to clinical trials with the objective of the identification of prognostic biomarkers associated with new therapies.
